<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The effect of the selective <z:chebi fb="0" ids="29101">Na(+)</z:chebi>/<z:chebi fb="0" ids="15378">H(+)</z:chebi> antiporter inhibitor 5-(N-ethyl-N-<z:chebi fb="0" ids="30353">isopropyl</z:chebi>)-<z:chebi fb="0" ids="2639">amiloride</z:chebi> (EIPA) on <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>/reperfusion injury was evaluated in the Mongolian gerbil </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">Ischemia</z:e> was induced in unanaesthetized gerbils by a 5-min period of bilateral common carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> followed by reperfusion for 6 days </plain></SENT>
<SENT sid="2" pm="."><plain>Two groups of gerbils were injected intraperitoneally with either <z:chebi fb="0" ids="28262">dimethyl sulfoxide</z:chebi> (DMSO; 10 microl) or EIPA (5 mg/kg in 10 microl DMSO) 30 min prior to <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>The increase in locomotor activity in the EIPA-treated group was significantly less than that of the control group at both 24 h and 6-day post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The extent of CA1 pyramidal neuron loss was significantly reduced in the EIPA-treated group in comparison with that of DMSO treated controls </plain></SENT>
<SENT sid="5" pm="."><plain>These results suggest that EIPA can protect cerebral neurons from <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion injury and implicates <z:hpo ids='HP_0001941'>acidosis</z:hpo> and <z:chebi fb="0" ids="29101">Na(+)</z:chebi>/<z:chebi fb="0" ids="15378">H(+)</z:chebi> exchange as a causative factor in such injury </plain></SENT>
</text></document>